The impact of JAK2 V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation
Year: 2025
Type: article
Abstract: Treatment with pegylated interferon α resulted in a molecular response in 91% of patients with an average decrease in JAK2V61F VAF of 48.5% from baseline. In patients that discontinued treatment, the JAK2V617F VAF at the time of treatment discontinuation was the best indicator of durable remission over the 6-month follow-up period. Created with SMART Servier Medical Art (https://smart.servier.com/).
Source: British Journal of Haematology
DOI: 10.1111/bjh.70198
Authors: Ryan Brown, Rebekah Bennett, Clare Crean, Andrew Hindley, Julie McGimpsey, Nicholas Cunningham, Aaron Niblock, Suzanne McPherson, Kathryn Boyd, Allister Foy, Ciaren Graham, Graeme Greenfield, Mary Frances McMullin, Mark A. Catherwood
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
OpenAlex ID: W4415499843